The clinical safety and efficacy of BA3011, alone or in combination with PD-(L)1 blockade, is being evaluated in clinical studies involving patients with NSCLC (Phase II, NCT04681131), ovarian cancers (Phase II, NCT04918186), solid tumors (Phase I NCT03425279), and soft tissue and bone sarcomas (Phase II, NCT03425279). Here, CD274 is linked to ovarian carcinoma.